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We agree with Schwartz and Landrigan that 
there is a need for change in the regulatory 
system for chemicals used in products in the 
United States. Bisphenol A (BPA) is one of 
thousands of chemicals of concern, but it 
provides a striking example of what happens 
when there is no requirement for premarket 
testing. Full estrogenic activity was demon‑
strated for BPA when it was tested for use 
as a pharmaceutical drug in 1936, which 
should have precluded its use in the wide 
range of products that results in continuous 
exposure (Stahlhut et al. 2009). The find‑
ings we reported in our article (Taylor et al. 
2011) show that clearance of BPA in mice, 
monkeys, and humans does not differ, and 
years of research has demonstrated that mice 
and rats are valid models for predicting the 
long‑term adverse consequences of develop‑
mental exposure to estrogenic chemicals. A 
vast and rapidly growing number of stud‑
ies with experi mental animals (Richter et al. 
2007) and humans (Braun and Hauser 2011) 
report adverse effects later in life as a result of 
exposure to BPA during development.
In the 2003–2004 National Health and 
Nutrition Examination Survey (NHANES) 
study, the Centers for Disease Control and 
Prevention estimated that 93% of people in 
the United States are exposed to BPA, with 
higher exposures in children than adults. 
The potential exposure of fetuses and infants 
to BPA is especially concerning because 
BPA is not metabolized effectively dur‑
ing these highly sensitive stages of human 
development. Our data (Taylor et al. 2011) 
indicate that to reach the median serum 
levels of unconjugated (bioactive) BPA 
reported in multiple biomonitoring studies 
(Vandenberg et al. 2010), exposure must 
be far higher than predicted by the Food 
and Drug Administration (FDA) based on 
its risk assessment of BPA (FDA 2008); 
these govern ment estimates (FDA 2008) are 
based on kinetics after acute oral exposure 
and the assumption that food and beverage 
packaging is the only source of BPA expo‑
sure. However, data from the 2003–2004 
NHANES (Stahlhut et al. 2009) confirmed 
that BPA exposure is likely to be from mul‑
tiple sources—including thermal receipt 
paper—and there is evidence that in adults 
different forms of exposure do not have the 
same meta bolic profile (Sieli et al. 2011).
We find it disturbing that government 
agencies continue to argue that the public 
should not be concerned about BPA because 
daily exposures are below “safe” levels. This 
conclusion is based on flawed studies using 
outdated approaches. We agree with Schwartz 
and Landrigan that we have to stop repeat‑
ing the same mistakes made previously with 
chemicals such as lead, for which, after 
decades of repeatedly lowering “safe” exposure 
estimates, the current predicted “safe” level is 
still above levels now known to cause adverse 
effects. For endocrine‑disrupting chemicals 
there are no threshold doses below which 
exposures are safe (Sheehan 2006), a reality 
that regulators are unwilling to acknowledge.
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Child Behavior 
http://dx.doi.org/10.1289/ehp.1104409
In his commentary, Weiss (2012) dis‑
cusses results of the recent Food and Drug 
Administration (FDA) evaluation of the pos‑
sible association between artificial food color 
additives (AFCs) and adverse behaviors in 
children, including those related to hyper‑
activity. The stated aim of the commentary 
is “to examine the basis of the FDA’s posi‑
tion, the elements of the review that led to its 
decision and that of the committee, and the 
reasons why this is an environmental issue.” 
In the commentary, however, a) the FDA’s 
petition review and safety assessment pro‑
cesses are misconstrued; b) the range of nor‑
mal behaviors and the levels at which these 
behaviors can be considered adverse are not 
distinguished, and comparisons that cloud 
the distinction are unsupported; c) exam‑
ples from individual studies are used out of 
context or irrespective of the conclusions 
expressed by the authors; d) specific results 
are cited from studies the FDA concluded 
were fundamentally flawed; and e) compre‑
hensive reviews by other scientific panels are 
not mentioned. As a result, the viewpoint 
presented does not properly characterize the 
public health issue, the FDA’s evaluation 
and conclusions, or the processes involved, 
including the FDA’s proposed actions. This 
letter addresses as many general errors, omis‑
sions, and apparent flaws in the commentary 
as space permits. 
In 2008, the Center for Science in the 
Public Interest (CSPI) petitioned the FDA 
to ban eight AFCs based primarily on results 
from clinical challenge studies on behavioral 
effects of these chemicals in children with a 
history of hyper activity disorders or related 
behavioral problems (CSPI 2008). The peti‑
tion also cited studies that tested potential 
